Spots Global Cancer Trial Database for squamous cell cancer
Every month we try and update this database with for squamous cell cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck | NCT04435938 | Head and Neck N... Squamous Cell C... Squamous Skin C... | Stereotactic Bo... | 60 Years - | McMaster University | |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | NCT03370276 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Head and Neck S... Squamous Cell C... Head and Neck C... | Nivolumab Cetuximab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study | NCT03467529 | Esophagus Cance... | Non interventio... | 18 Years - | Nantes University Hospital | |
| A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients | NCT01283906 | Oral Mucositis | MuGard Control Rinse | 18 Years - | Access Pharmaceuticals, Inc. | |
| Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer | NCT05932511 | Squamous Cell C... Squamous Cell C... Skin Cancer Non-melanoma Sk... | 30% ascorbic ac... | 18 Years - 85 Years | Center for Biomedical Research, Inc. | |
| RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus | NCT00559351 | Esophageal Neop... Squamous Cell C... | transthoracic e... neoadjuvant che... neoadjuvant che... | 18 Years - 75 Years | Ministry of Scientific Research and Information Technology, Poland | |
| Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer | NCT00591149 | Head and Neck C... Carcinoma, Squa... | Oxaliplatin Docetaxel Cetuximab | 18 Years - | University of Kansas Medical Center | |
| Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer | NCT00485485 | Head and Neck C... Squamous Cell C... | Imatinib Mesyla... Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer | NCT01384708 | Squamous Cell C... | proflavine | 18 Years - | Anandasabapathy, Sharmila, M.D. | |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | NCT03935893 | Gastric Cancer Colorectal Canc... Pancreatic Canc... Sarcoma Mesothelioma Neuroendocrine ... Squamous Cell C... Merkel Cell Car... Mismatch Repair... Microsatellite ... | Tumor Infiltrat... Fludarabine + C... | 18 Years - 75 Years | University of Pittsburgh | |
| Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer | NCT00507858 | Head and Neck C... | Pemetrexed Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer | NCT00401401 | Head and Neck C... Squamous Cell C... | zalutumumab cisplatin Radiotherapy | 18 Years - | Genmab | |
| Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | NCT02837042 | Penile Squamous... | Pembrolizumab | 18 Years - | University of Alabama at Birmingham | |
| Patient Evaluation for Head and Neck Surgery Branch Studies | NCT00011492 | Head and Neck N... Pharyngeal Canc... Oral Cancer Carcinoma, Squa... Laryngeal Cance... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer | NCT00401401 | Head and Neck C... Squamous Cell C... | zalutumumab cisplatin Radiotherapy | 18 Years - | Genmab | |
| Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer | NCT00661427 | Head and Neck Squamous Cell C... | cetuximab cetuximab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study | NCT05761132 | Vulva Cancer Vulva Neoplasm Squamous Cell C... | Pembrolizumab | 18 Years - 90 Years | Leiden University Medical Center | |
| R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | NCT06398418 | Melanoma Basal Cell Carc... Squamous Cell C... Melanoma Recurr... Basal Cell Canc... Squamous Cell C... | R-5780 | 18 Years - 80 Years | Rise Therapeutics LLC | |
| Using MC1R Genotype to Impact Melanoma Risk Behavior | NCT03509467 | Melanoma (Skin) Squamous Cell C... Squamous Cell C... Skin Cancer Basal Cell Carc... Basal Cell Canc... | Personalized In... Standard Inform... DNA Extraction ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Using MC1R Genotype to Impact Melanoma Risk Behavior | NCT03509467 | Melanoma (Skin) Squamous Cell C... Squamous Cell C... Skin Cancer Basal Cell Carc... Basal Cell Canc... | Personalized In... Standard Inform... DNA Extraction ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy | NCT00530283 | Squamous Cell C... | PET-CT | 18 Years - | AHS Cancer Control Alberta | |
| A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck | NCT04435938 | Head and Neck N... Squamous Cell C... Squamous Skin C... | Stereotactic Bo... | 60 Years - | McMaster University | |
| OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer | NCT00076310 | Head and Neck C... | Docetaxel OSI-774 Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Zalutumumab in Patients With Non-curable Head and Neck Cancer | NCT00382031 | Head and Neck C... Squamous Cell C... | Zalutumumab Control | 18 Years - | Genmab | |
| A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients | NCT01283906 | Oral Mucositis | MuGard Control Rinse | 18 Years - | Access Pharmaceuticals, Inc. | |
| Everolimus Versus Placebo in Head and Neck Cancer | NCT01111058 | Head and Neck C... | Everolimus (RAD... Placebo | 18 Years - | University of Chicago | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy | NCT00530283 | Squamous Cell C... | PET-CT | 18 Years - | AHS Cancer Control Alberta | |
| Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | NCT04391049 | Advanced Esopha... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... Squamous Cell C... Squamous Cell C... | Carboplatin Paclitaxel Radiation Thera... Telomerase-spec... | 18 Years - | NRG Oncology | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer | NCT00401401 | Head and Neck C... Squamous Cell C... | zalutumumab cisplatin Radiotherapy | 18 Years - | Genmab | |
| Zalutumumab in Non-curable Patients With SCCHN | NCT00542308 | Head and Neck C... Squamous Cell C... | Zalutumumab | 18 Years - | Genmab | |
| Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations | NCT04357873 | Squamous Cell L... Vulvar Cancer Penile Cancer Cervix Cancer Head and Neck S... Anal Cancer | pembrolizumab; ... | 18 Years - | UNICANCER | |
| Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | NCT02837042 | Penile Squamous... | Pembrolizumab | 18 Years - | University of Alabama at Birmingham | |
| Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study | NCT03467529 | Esophagus Cance... | Non interventio... | 18 Years - | Nantes University Hospital | |
| Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer | NCT00591149 | Head and Neck C... Carcinoma, Squa... | Oxaliplatin Docetaxel Cetuximab | 18 Years - | University of Kansas Medical Center | |
| Functional Outcomes Following Anal Cancer Treatment | NCT01853059 | Anal Cancer | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | ||
| Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy | NCT01358097 | Head and Neck C... Oropharyngeal C... Human Papilloma... Squamous Cell C... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | NCT04391049 | Advanced Esopha... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... Squamous Cell C... Squamous Cell C... | Carboplatin Paclitaxel Radiation Thera... Telomerase-spec... | 18 Years - | NRG Oncology | |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors | NCT04116320 | Melanoma Breast Cancer Merkel Cell Car... Squamous Cell C... Non Small Cell ... Cervical Cancer Urothelial Carc... Ovarian Cancer Hepatocellular ... Small-cell Lung... Microsatellite ... Gastric Cancer Esophageal Canc... | Echopulse Poly ICLC Standard of Car... | 18 Years - | University of Virginia | |
| Everolimus Versus Placebo in Head and Neck Cancer | NCT01111058 | Head and Neck C... | Everolimus (RAD... Placebo | 18 Years - | University of Chicago | |
| Safety Study of Modified Vaccinia Virus to Cancer | NCT00574977 | Melanoma Breast Cancer Head and Neck S... Liver Cancer Colorectal Canc... Pancreatic Aden... | Vaccinia virus ... Vaccinia virus ... Vaccinia virus ... | 18 Years - | University of Pittsburgh | |
| RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus | NCT00559351 | Esophageal Neop... Squamous Cell C... | transthoracic e... neoadjuvant che... neoadjuvant che... | 18 Years - 75 Years | Ministry of Scientific Research and Information Technology, Poland | |
| Using MC1R Genotype to Impact Melanoma Risk Behavior | NCT03509467 | Melanoma (Skin) Squamous Cell C... Squamous Cell C... Skin Cancer Basal Cell Carc... Basal Cell Canc... | Personalized In... Standard Inform... DNA Extraction ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
